CAS Number118292-40-3
SynonymsAvage; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[(4,4-diméthyl-3,4-dihydro-2H-thiochromén-6-yl)éthynyl]pyridine-3-carboxylate d'éthyle; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate; Tazorac; Tazarotene; Zorac; Ethyl-6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethinyl]pyridin-3-carboxylat; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; MFCD00867628
Molecular FormulaC21H21NO2S
Molecular Weight351.46
Purity≥98 (HPLC)%
Density1.2±0.1 g/cm3
Boiling Point499.8±45.0 °C at 760 mmHg
Melting Point97-98ºC
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 118292-40-3 |
| Catalog No. | 2A-9059665 |
| Chinese Name | 他扎罗汀 |
| Synonyms | Avage; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 6-[(4,4-diméthyl-3,4-dihydro-2H-thiochromén-6-yl)éthynyl]pyridine-3-carboxylate d'éthyle; 6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate; Tazorac; Tazarotene; Zorac; Ethyl-6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethinyl]pyridin-3-carboxylat; ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate; MFCD00867628 |
| Molecular Formula | C21H21NO2S |
| Molecular Weight | 351.46 |
| Purity | ≥98 (HPLC) |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 499.8±45.0 °C at 760 mmHg |
| Melting Point | 97-98ºC |
| Appearance | powder |
| Storage Condition | Store at +4°C |
| Application | Tazarotene is a selective retinoic acid receptor (RAR) agonist used to treat plaque psoriasis and acne vulgaris. |
| HTC | 2942000000 |
| SMILES | S1CCC(c2c1ccc(c2)C#Cc3ncc(cc3)C(=O)OCC)(C)C |
| InChI | 1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3 |
| InChI Key | OGQICQVSFDPSEI-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| MSDS | msds/59665_1_118292_40_3.pdf |
| Bioactivity | Tazarotene is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR Research Areas >> Inflammation/Immunology In Vitro Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer[1]. In human epidermal cell cultures, tazarotene suppresses the gene expression of 2 marker proteins, MRP-8 (calgranulin A) and SKALP (skin derived anti-leukoproteinase), highly elevated in psoriatic epidermis[2]. In Vivo Topical gel application provides direct delivery of tazarotene into the skin. At 10 hours after a topical application of 0.1% tazarotene gel to the skin of healthy individuals and patients with psoriasis, approximately 4 to 6% of the dose resides in the stratum corneum and 2% of the dose distributed to the viable epidermis and dermis. Tazarotene is designed to undergo rapid and complete metabolism to its active metabolite tazarotenic acid. Tazarotenic acid has a short systemic residence time and limited tissue distribution in animals[3].When topically applied, tazarotene blocks the induction of ornithine decarboxylase (ODC) activity by the tumour promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) in the epidermis of the hairless mouse[3]. References [1]. Talpur R, et al. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):195-210. [2]. Nagpal S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acidreceptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec;7(12):1783-91. [3]. Tang-Liu DD, et al. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 Oct;37(4):273-87. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 499.8±45.0 °C at 760 mmHg Melting Point 97-98ºC Molecular Formula C21H21NO2S Molecular Weight 351.462 Flash Point 256.1±28.7 °C Exact Mass 351.129303 PSA 64.49000 LogP 6.22 Vapour Pressure 0.0±1.3 mmHg at 25°C Index of Refraction 1.625 InChIKey OGQICQVSFDPSEI-UHFFFAOYSA-N SMILES CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1 Storage condition Store at +4°C |
| Use of | Tazarotene is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Properties Articles49 Name tazarotene Synonym More Synonyms Tazarotene Biological Activity Description Tazarotene is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> RAR/RXR Research Areas >> Inflammation/Immunology In Vivo Topical gel application provides direct delivery of tazarotene into the skin. At 10 hours after a topical application of 0.1% tazarotene gel to the skin of healthy individuals and patients with psoriasis, approximately 4 to 6% of the dose resides in the stratum corneum and 2% of the dose distributed to the viable epidermis and dermis. Tazarotene is designed to undergo rapid and complete metabolism to its active metabolite tazarotenic acid. Tazarotenic acid has a short systemic residence time and limited tissue distribution in animals[3].When topically applied, tazarotene blocks the induction of ornithine decarboxylase (ODC) activity by the tumour promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) in the epidermis of the hairless mouse[3]. References [1]. Talpur R, et al. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):195-210. [2]. Nagpal S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acidreceptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec;7(12):1783-91. [3]. Tang-Liu DD, et al. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 Oct;37(4):273-87. Chemical & Physical Properties Molecular Formula C21H21NO2S Exact Mass 351.129303 PSA 64.49000 Index of Refraction 1.625 InChIKey OGQICQVSFDPSEI-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| acid chloride | 535961-78-5 | 2A-1059648 |
| ZINCON | 135-52-4 | 2A-9059649 |
| fingolimod | 162359-55-9 | 2A-9059651 |
| Fingolimod HCL | 162359-56-0 | 2A-9059653 |
| 3-Methyl Phenethyl Ester | 71835-85-3 | 2A-9059659 |
| Antimycin A4 | 27220-59-3 | 2A-9059666 |
| Perchloryl fluoride | 7616-94-6 | 2A-9059669 |
| Alpha-lactalbumin | 9013-90-5 | 2A-9059670 |
| (Z)-3-(3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1H-inden-4-yl)-2-methyl-pro p-2-enoic acid | 10-07-1 | 2A-9059671 |
| H-1152Glycyl, Dihydrochloride | 913844-45-8 | 2A-9059672 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS